Kinetics of BCR-ABL transcript levels were determined in 19 patients with chronic myeloid
leukemia (CML) treated with imatinib for chronic (CP) or accelerated phase (AP). Patients …

Survival among chronic myelogenous leukemia (CML) patients can be linked to the
reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high …

Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …

We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …

Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …

Abstract Abstract 1680 We studied BCR-ABL1 transcript levels in patients with CML in
chronic phase at 3, 6 and 12 months after starting imatinib to identify molecular milestones …

The optimal management of malignant haematological disorders depend on the degree of
tumor load reduction after therapy. Chronic myeloid leukemia constitutes a clinical model for …

Accurate quantification of minimal residual disease (MRD) during treatment of chronic
myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR …

The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …

Purpose: The early BCR-ABL1 reduction had the prognostic impact of the chronic-phase
chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early …